Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…
Headline
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement…
News
Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis…
News
The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via…
Headline
The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug…